NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Independent reports  «  1  2  3  » 
found files: 47
»07/08/2008 [Independent reports]
China: New Regulations on Money Flows by: Michael Pettis

For a couple of weeks now there have been rumors and reports about new foreign exchange regulations being put into place, partly to limit hot money inflows and partly, once these begin to reverse, to make it more difficult for money to leave. Yesterday SAFE announced a new set of measures. Thursday’s South China Morning Post says the following about the announcement: China has issued new controls on transfers of foreign currencies, moving to contain growth in its foreign exchange reserves and curb speculative inflows blamed on fuelling inflation. The new rules, issued late Wednesday with immediate effect, call for penalties of up to 30 per cent of the capital involved in any unauthorised inward or outward foreign currency transfers. “As China’s economy becomes more internationalized and the movement of international capital flows accelerates, there is a need to improve the system and oversight of multinational capital movements,” the State Administration of Foreign Exchange, or SAFE, said in a statement posted on its website. The new regulations appear broader in scope than new limits announced by SAFE last month that called for authorities to check invoices to ensure they are not being inflated as an excuse to bring unauthorised money into the country. The new rules order government departments to simplify regulations on foreign direct investment and authorises them to crack down on illegal transactions. Last Friday the State Council said it was revising the rules concerning capital inflows and outflows, and this was generally interpreted as revising the regulations so as to allow the authorities to impose emergency restrictions on a sudden outpouring of money leaving the country. It is clearly important for SAFE to have some handle on inflows and outflows, but I am worried that most policy-makers continue to believe that rapid outflows leading to a 1997-style crisis is the only, or main, risk Cgina faces in relation to the current hot money inflow. In fact in my opinion the main risk is that these inflows have created unsustainable and vulnerable structures within the domestic banking system, in which case the risk of massive outflows is only part of the problem. The real problem is excess lending leading to misallocated capital, over investment, and what Hyman Minsky termed “Ponzi” debt structures, which are clearly already happening, if the evidence of SMEs borrowing at rates of 80% or more suggests anything. The problem is that under these conditions we could easily see a sudden rise in inventories, non-performing loans, capital hoarding, and faulty debt structures among corporations – mainly small and medium enterprises, I would guess. Unfortunately, in my opinion, the only adjustments that will prevent the system from getting worse – specifically a revaluation of the RMB to the point where inflows subside or even slightly reverse – have been put off for so long that it is becoming increasingly hard to see how the authorities will manage an adjustment without triggering problems in the banking sector. At any rate I know that it is getting increasingly difficult to bring in money for my business here in Beijing. I have a small, independent CD label specializing in developing the Beijing new and experimental music scenes. It is officially registered as a cultural institution (all media companies require that or a similar registration), and we regularly bring in money to pay for operations and production costs, but we have to work harder than ever to bring money in. Unfortunately the capital regulations do not easily distinguish between investors bringing in money to fund real activities in China and investors bringing in money to bet on RMB appreciation. I recognize the desperate need of the PBoC to regain some semblance of control over the money supply, but there are economic costs to doing so, especially onerous for small companies like mine. Meanwhile both HSBC and RBS, according to Bloomberg, have issued reports arguing that RMB forward contracts (NDFs) are priced low enough to offer “clear value”. The recent slowdown in RMB appreciation has convinced many investors to lower their 6-month and 1-year expectations for RMB appreciation, but – and I agree with HSBC and RBS if this is their argument – the reduced pace of appreciation is not sustainable and soon enough, probably before the end of the year, the debate about what to do with the RMB will re-ignite. This will lead to faster appreciation one way or the other. But for now policy-makers clearly think enough is enough on the appreciation front. Tuesday’s People’s Daily had a very revealing interview with Liu He, vice-minister of the Office of the Central Leading Group of Financial and Economic Affairs, which was carried in a lot of other local papers. Mr. Liu clearly seems to believe (or is repeating the government’s position) that China needs to loosen up further on the monetary and credit front. He says, in response to a question about Hu Jintao’s recent statement about the need to “keep policy stable” that “There is no need to further tighten the marco-control measures. Given the economic environment, the current measures are already appropriate.” In Beijing, it seems to me, the phrase “current measures are already appropriate” is usually code for policy recommendations to relax credit limits and slow RMB appreciation. In case the message was ambiguous, he added “At the moment, we should not rush more tightening measures.” He also repeated the by-now well-worn phrase: “We shouldn't sacrifice development to curb inflation.” This is certainly not something anyone would argue against, of course, further and balanced economic development is the key issue for China, but the implicit dichotomy is a false one. The fight against inflation is necessary precisely to ensure continued economic development. It is not an alternative to development. The most worrying part of the interview was, in my opinion, the following: Q: Do you think it's possible to curb excessive inflation by the end of the year? A: First of all, we should identify the main reason of the inflation. It's largely due to the depreciation of the US dollar, which triggers price rises of primary goods. For us, the key to deal with inflation is to stabilize our policy, ensure supply, subsidize the poor and adjust prices. We should also tame the public's inflation expectations. We should not be afraid of price rises as the adjustment of some underpriced products is unavoidable. But it's possible for inflation to moderate in the second half as oil price is falling and domestic agricultural supply is recovering. Inflation may well ease by the end of the year. Given that Chinese inflation has occurred mostly in domestic food prices, little of which is imported, and that many commodity prices, including oil, are price controlled, so that there is little to no pass-through in local costs, it is something of a shock to me that anyone believes that Chinese inflation is caused by a weakening dollar (and even more of a shock that this claim is used to buttress the argument against further appreciation of the RMB). It is also worrying to me that in the policy response to fighting inflation, taming inflationary expectations is considered a major concern, whereas nothing is said about the role of capital inflows in expanding the domestic money base. I remember in my teenage years in the 1970s there was a belief in the US that then-rising inflation was largely an oil price and expectation problem, and so various administrations jawboned, imposed price controls, wore “Whip Inflation Now” buttons, and did everything else except adjust monetary policy to kill off inflation. It didn’t work. I am not going to pretend that in those years I was more interested in Nixon’s monetary policy than in the rumored upcoming Spanish tour by the Rolling Stones (I was living in Spain then – and unfortunately a sudden burst of ETA terrorism killed plans for the Rolling Stones tour), but I do remember how ineffective those measures turned out to be. I guess I don’t really believe in “inflationary expectations” as a major cause of inflation. At the end of the interview, Mr. Liu did point out to an important issue that needs to be addressed: “In the second half, we need to push forward reforms in the financial sector. Presently, SMEs are usually the first victims of credit tightening measures. This reflects the rigidity of China's financial system. Moreover, we need to push forward reforms of the pricing mechanism for energy and resources products.” I think he is certainly right to be concerned about the unequal access to capital for SMEs, although I worry that he is pointing that out mainly to support an argument for credit loosening. It has been an eventful week in the run-up to the Olympics. Beijing is spruced up, traffic has improved dramatically, the weather is not too bad, most people are in a festive mood (although not artists and musicians – small clubs and CD shops specializing in Beijing art and music are being closed, presumably because the authorities believe foreign visitors will be more impressed with clean, well-scrubbed middle-brow entertainment than with the messy and chaotic cultural vitality Beijing typically exhibits). Even the stock market has been tame and well-mannered, if a little grumpy. It market was slightly up today (0.3%), following a relatively good day yesterday (up 1.1%), although overall for the week to date it is down 2.6%...   more»

»15/08/2008 [Independent reports]
Zoll's Undiscovered Growth: Heartbeating Its Way to Olympic Status

There are a little over 1.3 billion people living in China today. To put this in its proper perspective, there are only 6.7 billion people in the world today. China represents a full 20% of the world's population, so one in every five people on the planet is a resident of China. Moreover, the strong pressure within China to show the world it is an economic force is obvious with the grandiosity that is the Beijing Olympics. This new mindset, coupled with a new health care reform plan, has provided a unique opportunity for companies to obtain a presence within this new health care system. The opportunity has always been there, yet it has been always difficult to pinpoint the right company to obtain a government backing. Understanding the Chinese system is paramount point for western corporations seeking to obtain a preeminent and worthwhile position to generate above average return on capital investments. This is where Zoll Medical Corp. comes in. The corporation has already obtained government backing and orders for many products from major hospitals in China. More important, the health care system is developing a synergy with Zoll's product line. Taking a step back: Focusing on Health Care Structure Now that China has moved into a more capitalistic, entrepreneurial era, hospitals have been told that they have to finance some of their own costs. This is not an easy process for hospitals or for patients. Patients are now being asked to pay for some of their care. There is currently no system of private health insurance, although many firms are looking to start such programs. The alarming thing in China is the almost total absence of primary care. Even in cities, there are no independent doctors' offices or neighborhood clinics, so people have to go to the hospital for every health care need. Since there is little in the way of appointment systems, crowding and confusion occur. An enormous amount of resolve and money would be needed to correct this problem. The new health care reform scheme features basic concepts including adhering to the orientation of serving the people, ensuring the "non-profit" nature of public medical institutions, cutting hospitals' involvement in drug sales, increasing governmental responsibility and input, and establishing a basic medicare network for the whole population. The spread is higher Large cities such as Beijing are well served with both general and specialist hospitals. Specialist hospitals, which are equivalent to tertiary care referral centers in the West, have excellent equipment and technology: they routinely perform cardiac surgery, angioplasty, and transplant surgery. In many rural areas, there is a structured system of local and county hospitals with increasing levels of expertise as you go up through the system. However, there are areas of extreme poverty where the level of care leaves much to be desired. In the provinces furthest from Beijing, hospitals have little in the way of modern equipment, or even modern plumbing. Zoll designs, manufactures, markets, and sells non-invasive resuscitation devices and related software solutions in the United States and internationally. The company announced today that the ZOLL M Series® defibrillator has been installed in a number of high profile EMS centers and hospitals in the People's Republic of China. Given the health care structure, the lack of direct access from patients to a full-service medical facility allows Zoll's products to shine and become a primary brand. Moreover, Zoll is the premier provider during the Beijing Olympics; in terms of strategy and execution the company has situated itself well with the government to become an integral aspect in the country's desire to reform and expand health care. Already, a number of hospitals and emergency medical service centers in China have adopted its non-invasive cardiac support pump. The Chelmsford, Mass.-based medical device company reported that its AutoPulse cardiac support pump was approved by China's State Food and Drug Administration late last year. Since then the Beijing EMS Center, the Shenyang EMS Center, the Xinjiang EMS Center, the Shanghai Zhongshan Hospital and the Guangzhou Nanfang Hospital have installed the device. Perception is Everything While many companies are said to be expanding into Asia, how many of them have executed? How many of them have the trust and backing of the communistic regime? How many of them have premier hospitals adopting them, thus establishing themselves as a recognized brand? The answer is that there are many who expand into China in hope of obtaining a "Chinese premium" in valuations, but few have established a brand name and established government backing of their product lines. First movers into this territory usually obtains the higher premium and edge in competition. We see this in Yum Brands (YUM) [owners of KFC, Pizza Hut and Taco Bell], which moved years ahead of its competition and is now one of the premier and better establishments of Western fast food in Asia. This same effect from Zoll's unique early movement and rapid adoption at the time of the Beijing Olympics not only establishes the company's viability but also its brand, which is the most important asset to any company. Listed as an intangible on the balance sheets, brand is really what separates the high growth from the medium profitable company. Corporate Lines Other divisions of ZOLL are equally strong. I do not want to overly focus on one or two products and lose sight of the overall picture. While the Chinese market is certainly compelling, we must also focus on whether or not the entire management team is competent and whether the firm, overall, is capable of sustaining higher income. The company, to date, has succeeded with strong revenues and earnings in its recent quarter report. While guidance was on the low end, that should be lauded as a smart decision by management (rather than promising high expectations and failing to perform later). While the overall investment community may fail to realize the importance of this, some of the major catalysts for equities are 1) overdelivering, 2) analyst initiations, and 3) increasing volume from market cap expansion. In Zoll we have the ingredients for all three factors to influence the stock as the equity grows and matures (meaning appreciating in price over time). First, it makes perfect sense for a leader to remain duly conservative given the current global economic backdrop. This tells me he is honest with himself and the firm. I view honesty and integrity to be major factors in assessing leaders. And as a CEO, you are the face of your firm. As far as I am concerned, the management team at Zoll should be commended for making the right decision for the firm in the long run rather than satisfying the models and desires for profit by the shareholders. When investing, remember, we are trading symbols and electronic letters that represent the underlying collateral that is the business under review. It pays no value to the prospects of these electronic symbols if the consistency of the collateral is in question. This is why I value consistency of earnings as superior to rapid short term growth that comes at the expense of many wise decisions. Capital flows and cost management by the firm are the most important views in my fundamental analysis. There are others, but I rank these two factors very high. Secondly, the firm is not well covered by any major institutional player. The only one that comes to mind is RBC, which covers ZOLL. But even there, the firm's analysis is often short, and incomplete in my opinion. Moreover, many fail to consistently update the firm and only release reports during earnings season, which is a must by default. Lastly, in terms of the pricing theory of equities, the company is expanding and establishing a new level with increasing volume. This tells me there are prospects of firms picking this up more. I use a more complex financial theory to view markets, but in a general sense, we can say that the price movement from $10-$35 is being established, with a strong risk/reward ratio in being one of the best performing stock in terms of price performance in its group. Wrapping up Establishing a strong acceptance from China to be used in its premier hospitals during the Beijing Olympics not only creates a premier brand for Zoll, but also a premier brand in the eyes of Asian regulators who seek to expand their health care program. Moreover, conservative and competent management decisions will bode well for Zoll as a stock, and create the necessary catalyst and perceptions to let Zoll become a performing stock in its group....   more»

»22/09/2008 [Independent reports]
China Biotech in Review: A Designated Hotspot

...   more»

»03/10/2008 [Independent reports]
Targetting China's Middle Classes

Peter Abrahamson doesn’t mind admitting that his company is targeting the newly rich. The Shanghai-based CEO of listed WA product marketer Helicon, Abrahamson has on-the-ground knowledge of the growing might of China’s middle classes, who have money to spend and are demanding the best. That includes the best in healthcare in a country with no national health scheme but a hospital infrastructure that is booming. “A tertiary hospital like the Royal North Shore or the Royal Prince Alfred (in Sydney) might have 200 beds,” Abrahamson says. “The bigger hospitals in China, the class three hospitals, might have 1200 beds. They are state of the art, brand new, very well resourced, have paperless systems and they treat hundreds and hundreds of patients a day.” The concept of medical insurance is starting to appear in China, Abrahamson says, but most currently pay out of their own pocket. And they are demanding the best. “They can afford it and they want the best. The doctors give them a choice: you can have this or that and this is how much it costs. All of the multinationals are there charging Western prices and going very well.” Helicon is not about to compete with the multinationals, who all have their own manufacturing facilities and sales staff on the ground, or with the enormous generic medicines market. “If you think of the number of Chinese people who are taking antibiotics or analgesics every day, it’s massive,” he says. “But they work on extremely fine margins and there is no way that a foreign company like ours could even think of competing in that area.” What Helicon is doing instead is identifying niche areas of need, and finding a registered product to fill it. In what the company calls special situation opportunities, Helicon is looking at areas like intensive care, emergency medicine, oncology and cosmetic surgery and finding gaps that a Western product can fill. In July, Helicon had its first licensed product approved for sale in China, the skin regeneration kit ReCell, developed by Professor Fiona Wood and Avita Medical (formerly known as Clinical Cell Culture). Helicon doesn’t make any products itself and calls itself a speciality pharmaceutical marketing company. It has licensed four products so far: ReCell; a collagen-based implantable sponge impregnated with the antibiotic gentamicin called Collatamp G, licensed from UK-US pharma EUSA Pharma; Volplex, a succinylated gelatin-based blood plasma substitute from Maelor of the UK; and a wound dressing with a potent bacteriostatic agent for surgical site infections from MedWrap. “We are in the ICU area and are actively looking for more products there; surgical infections are a huge market in China in particular; and then the cosmetic surgery area,” Abrahamson says. “So we have a strategy there for surgeons. We are also actively seeking products in the oncology area – drugs and diagnostics.” Collatamp has recently been licensed and Helicon is preparing a product dossier for submission to China’s State Food and Drug Administration (SFDA). This is a long and detailed process and is expected to last 18 months. To assist in the complex process of gaining regulatory approval, Helicon has appointed a regulatory partner called ChinaGate, which works with the likes of Bayer, 3M and Organon. Registration and the SFDA Helicon was founded in 2003 by Dr Saliba Sassine, also founder of Biotech International, now known as Brisbane’s Agenix, and WA biotech Phylogica. “He set the company up after a visit to China, where he was blown away by the extraordinary growth that was happening there,” Abrahamson says. “He saw the opportunity and he decided to develop a model where he could bring in Western-registered and proven medical products to the China market.” Abrahamson himself has been in pharmaceuticals for most of his career, most recently as managing director of Allegan in Australia and as regional vice president, based in Hong Kong. A non-executive director of the company is another well-known figure in the Australian pharma and healthcare sector, Dr Arthur Emmett, chair of the Asthma Cooperative Research Centre and former chair of Metabolic. The company has also recently appointed its first China-based employee, Dr Chen Qi, a medical doctor and surgeon who has headed up sales and marketing teams for Roche and Lilly. “He brings very valuable experience in how you do business in China, from product knowledge – he’s a very valuable addition,” Abrahamson says. “We have also appointed a business development manager in Switzerland and her role is to identify these small to medium-sized companies, and there are lots of those in Europe and in the US, and here.” At this stage of the company’s development – it listed on the ASX last September – Helicon is focusing on registered products that are proven in the market somewhere. In time, however, it will probably begin to look for products earlier in the development phase, as these can prove interesting and sometimes even cheaper. “The way the model works is that someone else takes the R&D risk, we own the license for China and we use third parties that are specialists in the area to do the registration,” he says. That registration is a difficult area. China’s SFDA has had a major shake-up in recent years and drug approvals have slowed for the time being. “The SFDA is now part of the Ministry of Health,” he says. “(Registration) used to be a fairly grey process where certain envelopes used to change hands, and then in 2004 the government really started to focus, in the healthcare area, on corruption. Now they have brought in a new system which is very similar to the US FDA in terms of registration and the sort of data you need. “You need to prove bioequivalence, you need to prove quality and so on. So it is all a lot more black and white than it used to be, which is great, but it has slowed down the system considerably. “But I’d prefer to be working on a level playing field, and wait, and then once you have approval you know that it’s done properly.”...   more»

»02/10/2008 [Independent reports]
Big Pharma Ranks China as Number One Destination in Asia for Pharmaceutical Outsourcing

Big pharmaceutical companies now rank China as the best location for outsourcing in Asia, followed by India, Korea and Taiwan, respectively, according to a newly released PricewaterhouseCoopers index. The index evaluates Asian countries according to cost, risk and market opportunity for the pharmaceutical industry. The index was published in a new PricewaterhouseCoopers report entitled "The Changing Dynamics of Pharma Outsourcing in Asia: Are You Readjusting Your Sights?" which found that Asia is emerging not just as a drug manufacturing powerhouse but a rival to the United States as a leading source of drug discovery and high-end innovation. Both clinical trial activity and investments by pharmaceutical companies to expand presence in Asia are accelerating, and the report suggests Asia outsourcing is moving up the value chain, as low-cost production is eclipsed by a broad range of factors, including market potential and R&D capacity as the drivers of growth. "Within five to ten years, we will be moving from 'made in China' to 'discovered in China'" said one pharmaceutical industry executive interviewed for the report. "Pharmaceutical companies need to make sure they are refining their strategies to make the most of the opportunities presented in Asian countries," said Michael Keech, director, PricewaterhouseCoopers global pharmaceutical and life sciences industry group. "China and India will continue to spearhead growth in the Asian pharmaceutical sector, but, alongside those countries, Singapore will maintain its position as a center for research and innovation. While the trio of India, China and Singapore are proving to be the 'hotspots' of the Asian pharmaceutical sector, other countries, notably Korea and Taiwan, are also going to be increasingly significant. The companies that will be most successful at making pharma outsourcing and location decisions will be those that are most adept at managing and mixing a range of contractual relationships and partnerships across a number of different locations." According to the report, pharmaceutical companies in the United States and other developed countries are facing an array of challenges that are constraining revenue growth, thus driving their need to look for new ways to boost drug discovery potential, reduce time to market, and minimize costs. For example, only nine of the 18 new treatments launched in the United States in 2006 came from the laboratories of the 13 companies that comprise the big pharma universe. The report highlights three significant developments that are shaping Asian pharmaceutical outsourcing: * The trend towards high-end innovation -- intellectual property (IP) concerns have previously inhibited this trend in pharma but, increasingly, such concerns are being overcome and major moves are being made by big pharmaceutical companies to increase their drug discovery investment in Asia. * Rapid expansion of clinical trials in Asia -- the volume of clinical trials being conducted in countries outside of Europe, North America and Japan has been growing rapidly in recent years with Asian countries leading much of the growth. China has overtaken India as one of the fastest-growing locations. By June 2008, China had 428 clinical trials registered on the website as under way and a cumulative total of 870 completed or ongoing trials compared with 737 in India. Cost has been a critical factor in this expansion. For example, clinical trials are estimated to be up to 50 percent cheaper in India compared to the U.S. * A scaling up of pharma manufacturing in Asia -- with an increased commitment to international standards, Asian contract manufacturing organizations (CMOs) are securing more outsourcing orders from big pharmaceutical companies. In India, for example, there are more than 100 FDA-approved pharmaceutical facilities -- the largest number in any country outside the U.S. The report shows that China and India, followed by Korea and Taiwan, are now delivering a number of benefits for the pharmaceutical industry including a pool of educated and qualified scientists, intellectual property (IP) law reform and market growth. These trends are outweighing factors that had previously inhibited development, principally uncertain regulatory frameworks and enforcement. Significant risks remain, but the report observes a growing convergence with international regulatory standards. However, the report's authors point out that such convergence is also being felt in labor markets, with the result that traditionally wide wage differentials, compared to developed country locations, are narrowing. Such convergence will continue to shrink the cost gap, prompted in part by the need for Asian countries to compete for 'high-end' skills in an international labor market. India, for example, is already finding it difficult to recruit in certain areas such as clinical research personnel. A full copy of the report is available for download at As well as the index, the report includes a detailed overview of each territory, grouped in the following sections: * The hot spot countries: China, India and Singapore; * The mature markets: Japan and Australia; and, * Other Asian countries: Korea, Taiwan, Malaysia, Thailand, Indonesia & Philippines....   more»

»17/11/2008 [Independent reports]
China to Emerge as Fourth Largest Western Drug Consumer by 2012

China is expected to become the world’s fourth largest western drug consumer by 2012 as aging population is growing in the country and people are increasingly opting western drugs...   more»

»19/11/2008 [Independent reports]
Big Pharma Steps Up China Investment

...   more»

»11/12/2008 [Independent reports]
High Growth Forecast for the China Vaccine Market Report, 2007-2009

China is the largest vaccine producer and consumer in the world. According to the statistics of the General Administration of Customs, China\'s total vaccine import and export volume reached 34,846 tons in the first five months of 2008...   more»

»15/12/2008 [Independent reports]
China Industrial-Output Growth Is Weakest Since 1999 (Update3)

By Kevin Hamlin and Li Yanping (Bloomberg) -- China’s industrial production grew at the weakest pace in almost a decade as export growth collapsed, increasing pressure on the government to do more to revive the slumping economy....   more»

»21/12/2008 [Independent reports]
It May Be Chinas Time to Leapfrog Ahead in Biopharma

As Greg Scott, Executive Editor, wrote last week, the 4th ChinaBio Investor Forum showed activity in China biopharma remains high. At the forum, young biopharmas showed off their innovation and VCs were interested. Still, it is true that the worldwide economic troubles are having an effect: IPOs are currently moribund and VC investments are trending lower. Nevertheless, at least at the Investment Forum, the general mood remained upbeat....   more»

»23/04/2009 [Independent reports]
The Problems and Potential of the China Pharmaceutical Industry

HEALTH POLICY OUTLOOK By Roger Bate, Karen Porter...   more»

»17/05/2009 [Independent reports]
China: Latest Hotspot for Western Biotech,

Asian countries such as India and Japan have gained notoriety for their talented scientists and innovative contributions to the life sciences. Now, a new contender is emerging as a potential industry leader....   more»

»03/07/2009 [Independent reports]
Foreign Pharmas Marching into Chinese Towns

While entry of multinational pharmaceutical companies into China has greatly improved the technologies, products and management of the country healthcare industry, it also causes significant impacts on Chinas own pharmaceutical industry. Foreign pharmaceutical companies are now gaining more and more market, equity and technology power in China, and furthermore, the new drugs market of China is now basically controlled by foreign players....   more»

»03/08/2009 [Independent reports]
BioSpectrumAsia Top 20 Vol. 2: Asia Life Sciences Industry employs 2.3 mn People

An independent look at how labour is deployed within the sector...   more»

»03/09/2009 [Independent reports]
China CRO industry booms as pharma demand heats up

Big Pharma needs to cut development spending and boost its presence in big new markets is driving sizzling hot growth rates for China contract research organizations....   more»

»24/09/2009 [Independent reports]
Clinical development trends in APAC in recessionary environment

With ‘green shoots’ (recovery from the economic downturn) appearing in the global economy, it is a good time to consider what is happening in the Asia Pacific (APAC) biopharma scene. Dr Ross Horsburgh...   more»

»21/09/2009 [Independent reports]
Biotech Companies with Developing Country Partners Better Positioned to Innovate and Thrive

Collaboration with health biotech companies in developing countries represents a major opportunity for companies in developed countries to strengthen their market reach and innovation potential, according to the findings of a new study. By BiotechDaily International staff writers...   more»

»14/12/2009 [Independent reports]
Primary healthcare sector in China surges ahead

Primary healthcare facilities concept, better known as Community Health Centers (CHC) and Community Health Stations (CHS) in urban China, was first initiated in 1997, to address the rising public cries towards increasingly unaffordable and inaccessible healthcare at the tertiary care hospitals in the urban cities. Thus, the Chinese government began to shift its focus from purely large general hospitals development to primary community healthcare....   more»

»08/01/2010 [Independent reports]
China\'s Vaccine Sector: How to Get in the Game

China vaccine sector will grow 25 percent annually, according to a report from Zero2IPO, a Chinese venture-capital firm. In 2012, the size of the market will reach \"8 billion yuan\", the report said....   more»

»20/01/2010 [Independent reports]
All Eyes on Chinese healthcare market

The overall compound annual growth rate of the pharmaceutical market (2009-2013), for its part, is projected to be 24%, with the market reaching an estimated $73 billion by 2013 (at constant exchange rates)....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.